Marjolein Y. V. Homs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marjolein Y. V. Homs has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Bas Groot Koerkamp
Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands
7 shared publications - Casper H. J. van Eijck
Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
4 shared publications - Leni van Doorn
Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
3 shared publications - Marc Gerard Besselink
Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
3 shared publications - Bert A. Bonsing
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
2 shared publications - Bianca Mostert
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Adjuvant Hepatic Arterial Infusion Pump Chemotherapy Without Systemic Therapy After Repeat Local Treatment for Patients With Liver-only Recurrence of Colorectal Cancer
Background: Approximately 30% of patients develop liver-confined recurrences after local treatment for colorectal liver metastases (CRLM), which may be reduced by adjuvant therapy. Hepatic arterial infusion pump (HAIP) chemotherapy delivers high-dose liver-directed chemotherapy. Objective: To investigate adjuvant HAIP chemotherapy without systemic therapy in patients with resectable liver-confined recurrence after prior local treatment of CRLM. Methods: This multicenter, single-arm phase II trial enrolled patients with resectable recurrent CRLM across 3 centers in the Netherlands. Patients with prior or present extrahepatic disease were excluded. Adjuvant HAIP with floxuridine was administered up to 6 cycles. The primary endpoint was hepatic disease-free survival (hDFS) estimated using the Kaplan–Meier method, with a prespecified efficacy boundary of 36 months. Results: Forty-five patients underwent local treatment followed by adjuvant HAIP chemotherapy without systemic therapy. Twenty-eight patients(62%) were treated for a first recurrent CRLM, and 17 patients for a second or higher. Twenty-five patients (56%) had ≥3 CRLM. All patients started HAIP chemotherapy, with a median of 6 cycles (interquartile range: 4 to 6). After a median follow-up of 38.7 months (95% CI: 33.0–42.3), the median hDFS was 16.5 months (95% CI: 9.1–25.8). The median progression-free survival was 14.0 months (95% CI: 7.7–23.0), and the 3-year overall survival was 71% (95% CI: 58%–87%). Initial recurrence included the liver in 23 patients (51%). HAIP implantation-related complications (Clavien–Dindo grade ≥3) occurred in 4 patients (9%), and HAIP chemotherapy-related complications (Common Terminology Criteria for Adverse Events grade ≥3) occurred in 6 patients (13%). Biliary sclerosis occurred in 4 patients; 3 required stent placement. Conclusion: Adjuvant HAIP chemotherapy without systemic therapy did not achieve the hypothesized hDFS in patients undergoing repeat local treatment for recurrent CRLM.
- 10 November 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Open AccessAdjuvant Hepatic Arterial Infusion Pump Chemotherapy Without Systemic Therapy After Repeat Local Treatment for Patients With Liver-only Recurrence of Colorectal Cancer
Background: Approximately 30% of patients develop liver-confined recurrences after local treatment for colorectal liver metastases (CRLM), which may be reduced by adjuvant therapy. Hepatic arterial infusion pump (HAIP) chemotherapy delivers high-dose liver-directed chemotherapy. Objective: To investigate adjuvant HAIP chemotherapy without systemic therapy in patients with resectable liver-confined recurrence after prior local treatment of CRLM. Methods: This multicenter, single-arm phase II trial enrolled patients with resectable recurrent CRLM across 3 centers in the Netherlands. Patients with prior or present extrahepatic disease were excluded. Adjuvant HAIP with floxuridine was administered up to 6 cycles. The primary endpoint was hepatic disease-free survival (hDFS) estimated using the Kaplan–Meier method, with a prespecified efficacy boundary of 36 months. Results: Forty-five patients underwent local treatment followed by adjuvant HAIP chemotherapy without systemic therapy. Twenty-eight patients(62%) were treated for a first recurrent CRLM, and 17 patients for a second or higher. Twenty-five patients (56%) had ≥3 CRLM. All patients started HAIP chemotherapy, with a median of 6 cycles (interquartile range: 4 to 6). After a median follow-up of 38.7 months (95% CI: 33.0–42.3), the median hDFS was 16.5 months (95% CI: 9.1–25.8). The median progression-free survival was 14.0 months (95% CI: 7.7–23.0), and the 3-year overall survival was 71% (95% CI: 58%–87%). Initial recurrence included the liver in 23 patients (51%). HAIP implantation-related complications (Clavien–Dindo grade ≥3) occurred in 4 patients (9%), and HAIP chemotherapy-related complications (Common Terminology Criteria for Adverse Events grade ≥3) occurred in 6 patients (13%). Biliary sclerosis occurred in 4 patients; 3 required stent placement. Conclusion: Adjuvant HAIP chemotherapy without systemic therapy did not achieve the hypothesized hDFS in patients undergoing repeat local treatment for recurrent CRLM.
- Open Access
The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact—A Nationwide, Retrospective Cohort Study
Background/Objectives: Stereotactic body radiotherapy (SBRT) aims to prolong overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC) with vascular contact without progression of disease after (m)FOLFIRINOX. The primary objective of this study was to determine the potential value of SBRT. Methods: This nationwide, retrospective cohort study included patients with PDAC without progression of disease after at least four cycles of (m)FOLFIRINOX. The study comprised two cohorts, the SBRT and the No SBRT group. A landmark analysis excluded patients with a follow-up or OS time less than 12 months to minimize immortal time bias in the SBRT group. The primary outcome was OS from diagnosis. Secondary outcomes were the histopathological characteristics after resection. Results: Overall, 331 patients were included, of whom 231 were in the landmark analysis. In the overall cohort, the median OS was 20.7 months in the SBRT group versus 15.7 months in the No SBRT group (p = 0.004). In the landmark analysis, the median OS was 23.2 months in the SBRT group compared to 22.3 months in the No SBRT group (p = 0.554). These results indicate the presence of immortal time bias in the overall cohort in favor of the SBRT group. In the subgroup after resection, ypT0-2 (95% versus 76.5% [p = 0.026]), ypN0 (75% versus 37.3% [p < 0.004]), and absence of perineural invasion (50% versus 68.6% [p = 0.015]) were more prevalent in the SBRT group. Conclusions: In a landmark analysis, including only patients who survived at least 12 months after diagnosis, we found no difference in median OS between (m)FOLFIRINOX-only and (m)FOLFIRINOX with consecutive SBRT.
Open AccessThe Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact—A Nationwide, Retrospective Cohort Study
Background/Objectives: Stereotactic body radiotherapy (SBRT) aims to prolong overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC) with vascular contact without progression of disease after (m)FOLFIRINOX. The primary objective of this study was to determine the potential value of SBRT. Methods: This nationwide, retrospective cohort study included patients with PDAC without progression of disease after at least four cycles of (m)FOLFIRINOX. The study comprised two cohorts, the SBRT and the No SBRT group. A landmark analysis excluded patients with a follow-up or OS time less than 12 months to minimize immortal time bias in the SBRT group. The primary outcome was OS from diagnosis. Secondary outcomes were the histopathological characteristics after resection. Results: Overall, 331 patients were included, of whom 231 were in the landmark analysis. In the overall cohort, the median OS was 20.7 months in the SBRT group versus 15.7 months in the No SBRT group (p = 0.004). In the landmark analysis, the median OS was 23.2 months in the SBRT group compared to 22.3 months in the No SBRT group (p = 0.554). These results indicate the presence of immortal time bias in the overall cohort in favor of the SBRT group. In the subgroup after resection, ypT0-2 (95% versus 76.5% [p = 0.026]), ypN0 (75% versus 37.3% [p < 0.004]), and absence of perineural invasion (50% versus 68.6% [p = 0.015]) were more prevalent in the SBRT group. Conclusions: In a landmark analysis, including only patients who survived at least 12 months after diagnosis, we found no difference in median OS between (m)FOLFIRINOX-only and (m)FOLFIRINOX with consecutive SBRT.
- Open Access
- 27 August 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (11) , 110419
Outcomes following exploratory surgery without subsequent resection in perihilar cholangiocarcinoma: A nationwide analysis
- 27 August 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (11) , 110419
Open AccessOutcomes following exploratory surgery without subsequent resection in perihilar cholangiocarcinoma: A nationwide analysis
- 27 March 2025
- Published by Springer Nature
- p. 129-141
Hepatic Arterial Infusion Drugs and Dosing
- Open Access
- 4 June 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 37 (10)
Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study
Definitive chemoradiotherapy (dCRT) is a potentially curative therapy for esophageal cancer. As indications for dCRT differ widely, it is challenging to draw conclusions on outcomes and survival. The aim of this study was to evaluate overall survival (OS) and recurrence patterns according to indications for treatment. Patients who underwent dCRT (50.4 Gy concomitant with carboplatin/paclitaxel) for esophageal cancer between 2012 and 2022 were identified. Indications for dCRT were: cervical tumor, irresectable disease, unfit for surgery, and patient and/or physician preference. The primary endpoint was OS calculated with the Kaplan–Meier method. Secondary endpoints included the proportion of patients that completed the dCRT regimen, 30- and 90-day mortality, and disease recurrence. One hundred and fifty-seven patients were included (72.6% esophageal squamous cell carcinoma) with a median follow-up of 20 months (IQR 10.0–43.9). The full dCRT regimen was completed by 116 patients (73.9%). Thirty- and 90-day mortality were 2.5% and 8.3%, respectively. Median and 5-year OS for all patients were 22.9 months (95% CI 18.0–27.9) and 31.4%, respectively. The median OS per indication was 23.7 months (95% CI 6.5–40.8) for patients with cervical tumors, 10.9 months (95% 0.0–23.2) for irresectable disease, 28.2 months (95% CI 12.3–44.0) for unfit patients, and 22.9 months (95% CI 15.4–30.5) for patients’ preference for dCRT (P = 0.11). Disease recurrence was observed in 74 patients (46%), located locoregionally (46%), distant (19%), or combined (35%). Patients who underwent dCRT had a 5-year OS of 31.4%, but OS differed according to indications for treatment with patients who had irresectable disease having the worst prognosis.
- 4 June 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 37 (10)
Open AccessOverall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study
Definitive chemoradiotherapy (dCRT) is a potentially curative therapy for esophageal cancer. As indications for dCRT differ widely, it is challenging to draw conclusions on outcomes and survival. The aim of this study was to evaluate overall survival (OS) and recurrence patterns according to indications for treatment. Patients who underwent dCRT (50.4 Gy concomitant with carboplatin/paclitaxel) for esophageal cancer between 2012 and 2022 were identified. Indications for dCRT were: cervical tumor, irresectable disease, unfit for surgery, and patient and/or physician preference. The primary endpoint was OS calculated with the Kaplan–Meier method. Secondary endpoints included the proportion of patients that completed the dCRT regimen, 30- and 90-day mortality, and disease recurrence. One hundred and fifty-seven patients were included (72.6% esophageal squamous cell carcinoma) with a median follow-up of 20 months (IQR 10.0–43.9). The full dCRT regimen was completed by 116 patients (73.9%). Thirty- and 90-day mortality were 2.5% and 8.3%, respectively. Median and 5-year OS for all patients were 22.9 months (95% CI 18.0–27.9) and 31.4%, respectively. The median OS per indication was 23.7 months (95% CI 6.5–40.8) for patients with cervical tumors, 10.9 months (95% 0.0–23.2) for irresectable disease, 28.2 months (95% CI 12.3–44.0) for unfit patients, and 22.9 months (95% CI 15.4–30.5) for patients’ preference for dCRT (P = 0.11). Disease recurrence was observed in 74 patients (46%), located locoregionally (46%), distant (19%), or combined (35%). Patients who underwent dCRT had a 5-year OS of 31.4%, but OS differed according to indications for treatment with patients who had irresectable disease having the worst prognosis.
- Open Access
- 3 April 2023
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 278 (6) , 1018-1023
Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival
Background and Objectives: A high systemic immune-inflammation index (SIII) at diagnosis of various cancers, including pancreatic cancer, is associated with poor prognosis. The impact of FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) chemotherapy or stereotactic body radiotherapy on this index is unknown. In addition, the prognostic value of changes in the SIII during treatment is unclear. In this retrospective analysis, we aimed to find answers regarding patients with advanced pancreatic cancer. Methods: Patients with advanced pancreatic cancer treated with FOLFIRINOX chemotherapy alone or with FOLFIRINOX chemotherapy followed by stereotactic body radiotherapy between 2015 and 2021 in 2 tertiary referral centers were included. Baseline characteristics, laboratory values at 3 time points during treatment, and survival outcomes were collected. The patient-specific evolutions of SIII and their association with mortality were assessed with joint models for longitudinal and time-to-event data. Results: Data of 141 patients were analyzed. At a median follow-up time of 23.0 months (95% CI: 14.6–31.3), 97 (69%) patients had died. Median overall survival was 13.2 months (95% CI: 11.0–15.5). During treatment with FOLFIRINOX, the log (SIII) was reduced by −0.588 (95% CI: −0.0978, −0.197; P = 0.003). One unit increase in log (SIII) increased the hazard ratio of dying by 1.604 (95% CI: 1.068–2.409; P = 0.023). Conclusions: In addition to carbohydrate antigen 19-9, the SIII is a reliable biomarker in patients with advanced pancreatic cancer.
- 3 April 2023
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 278 (6) , 1018-1023
Open AccessIncreasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival
Background and Objectives: A high systemic immune-inflammation index (SIII) at diagnosis of various cancers, including pancreatic cancer, is associated with poor prognosis. The impact of FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) chemotherapy or stereotactic body radiotherapy on this index is unknown. In addition, the prognostic value of changes in the SIII during treatment is unclear. In this retrospective analysis, we aimed to find answers regarding patients with advanced pancreatic cancer. Methods: Patients with advanced pancreatic cancer treated with FOLFIRINOX chemotherapy alone or with FOLFIRINOX chemotherapy followed by stereotactic body radiotherapy between 2015 and 2021 in 2 tertiary referral centers were included. Baseline characteristics, laboratory values at 3 time points during treatment, and survival outcomes were collected. The patient-specific evolutions of SIII and their association with mortality were assessed with joint models for longitudinal and time-to-event data. Results: Data of 141 patients were analyzed. At a median follow-up time of 23.0 months (95% CI: 14.6–31.3), 97 (69%) patients had died. Median overall survival was 13.2 months (95% CI: 11.0–15.5). During treatment with FOLFIRINOX, the log (SIII) was reduced by −0.588 (95% CI: −0.0978, −0.197; P = 0.003). One unit increase in log (SIII) increased the hazard ratio of dying by 1.604 (95% CI: 1.068–2.409; P = 0.023). Conclusions: In addition to carbohydrate antigen 19-9, the SIII is a reliable biomarker in patients with advanced pancreatic cancer.
- Open Access
- 28 December 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 181, 119-134
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma
- 28 December 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 181, 119-134
Open AccessA multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma
- Open Access
- 9 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (20) , 10902
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages were included in this study, of whom 25% showed progressive disease during FOLFIRINOX according to the RECIST criteria. MiRNA expression was analyzed in serum collected before the start and after one cycle of chemotherapy. In the discovery cohort (n = 12), a 352-miRNA RT-qPCR panel was used. In the validation cohorts (total n = 120), miRNA expression was detected using individual RT-qPCR miRNA primers. Before the start of FOLFIRINOX, serum miR-373-3p expression was higher in patients with progressive disease compared to patients with disease control after FOLFIRINOX (Log2 fold difference (FD) 0.88, p = 0.006). MiR-194-5p expression after one cycle of FOLFIRINOX was lower in patients with progressive disease (Log2 FD −0.29, p = 0.044). Both miRNAs were predictors of early tumor progression in a multivariable model including disease stage and baseline CA19-9 level (miR-373-3p odds ratio (OR) 3.99, 95% CI 1.10–14.49; miR-194-5p OR 0.91, 95% CI 0.83–0.99). MiR-373-3p and miR-194-5p did not show an association with OS after adjustment for disease stage, baseline CA19-9, and chemotherapy response. In conclusion, high serum miR-373-3p before the start and low serum miR-194-5p after one cycle are associated with early tumor progression during FOLFIRINOX.
- 9 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (20) , 10902
Open AccessSerum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages were included in this study, of whom 25% showed progressive disease during FOLFIRINOX according to the RECIST criteria. MiRNA expression was analyzed in serum collected before the start and after one cycle of chemotherapy. In the discovery cohort (n = 12), a 352-miRNA RT-qPCR panel was used. In the validation cohorts (total n = 120), miRNA expression was detected using individual RT-qPCR miRNA primers. Before the start of FOLFIRINOX, serum miR-373-3p expression was higher in patients with progressive disease compared to patients with disease control after FOLFIRINOX (Log2 fold difference (FD) 0.88, p = 0.006). MiR-194-5p expression after one cycle of FOLFIRINOX was lower in patients with progressive disease (Log2 FD −0.29, p = 0.044). Both miRNAs were predictors of early tumor progression in a multivariable model including disease stage and baseline CA19-9 level (miR-373-3p odds ratio (OR) 3.99, 95% CI 1.10–14.49; miR-194-5p OR 0.91, 95% CI 0.83–0.99). MiR-373-3p and miR-194-5p did not show an association with OS after adjustment for disease stage, baseline CA19-9, and chemotherapy response. In conclusion, high serum miR-373-3p before the start and low serum miR-194-5p after one cycle are associated with early tumor progression during FOLFIRINOX.
- Open Access
- 5 April 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-9
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy aims to reduce the risk of intrahepatic recurrence. A large retrospective propensity score analysis demonstrated that HAIP chemotherapy is particularly effective in patients with low-risk oncological features. The aim of this randomized controlled trial (RCT) --the PUMP trial-- is to investigate the efficacy of adjuvant HAIP chemotherapy in low-risk patients with resectable CRLM. This is an open label multicenter RCT. A total of 230 patients with resectable CRLM without extrahepatic disease will be included. Only patients with a clinical risk score (CRS) of 0 to 2 are eligible, meaning: patients are allowed to have no more than two out of five poor prognostic factors (disease-free interval less than 12 months, node-positive colorectal cancer, more than 1 CRLM, largest CRLM more than 5 cm in diameter, serum Carcinoembryonic Antigen above 200 μg/L). Patients randomized to arm A undergo complete resection of CRLM without any adjuvant treatment, which is the standard of care in the Netherlands. Patients in arm B receive an implantable pump at the time of CRLM resection and start adjuvant HAIP chemotherapy 4–12 weeks after surgery, with 6 cycles of floxuridine scheduled. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival, hepatic PFS, safety, quality of life, and cost-effectiveness. Pharmacokinetics of intra-arterial administration of floxuridine will be investigated as well as predictive biomarkers for the efficacy of HAIP chemotherapy. In a side study, the accuracy of CT angiography will be compared to radionuclide scintigraphy to detect extrahepatic perfusion. We hypothesize that adjuvant HAIP chemotherapy leads to improved survival, improved quality of life, and a reduction of costs, compared to resection alone. If this PUMP trial demonstrates that adjuvant HAIP chemotherapy improves survival in low-risk patients, this treatment approach may be implemented in the standard of care of patients with resected CRLM since adjuvant systemic chemotherapy alone has not improved survival. The PUMP trial is registered in the Netherlands Trial Register (NTR), number: 7493 . Date of registration September 23, 2018.
- 5 April 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-9
Open AccessAdjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy aims to reduce the risk of intrahepatic recurrence. A large retrospective propensity score analysis demonstrated that HAIP chemotherapy is particularly effective in patients with low-risk oncological features. The aim of this randomized controlled trial (RCT) --the PUMP trial-- is to investigate the efficacy of adjuvant HAIP chemotherapy in low-risk patients with resectable CRLM. This is an open label multicenter RCT. A total of 230 patients with resectable CRLM without extrahepatic disease will be included. Only patients with a clinical risk score (CRS) of 0 to 2 are eligible, meaning: patients are allowed to have no more than two out of five poor prognostic factors (disease-free interval less than 12 months, node-positive colorectal cancer, more than 1 CRLM, largest CRLM more than 5 cm in diameter, serum Carcinoembryonic Antigen above 200 μg/L). Patients randomized to arm A undergo complete resection of CRLM without any adjuvant treatment, which is the standard of care in the Netherlands. Patients in arm B receive an implantable pump at the time of CRLM resection and start adjuvant HAIP chemotherapy 4–12 weeks after surgery, with 6 cycles of floxuridine scheduled. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival, hepatic PFS, safety, quality of life, and cost-effectiveness. Pharmacokinetics of intra-arterial administration of floxuridine will be investigated as well as predictive biomarkers for the efficacy of HAIP chemotherapy. In a side study, the accuracy of CT angiography will be compared to radionuclide scintigraphy to detect extrahepatic perfusion. We hypothesize that adjuvant HAIP chemotherapy leads to improved survival, improved quality of life, and a reduction of costs, compared to resection alone. If this PUMP trial demonstrates that adjuvant HAIP chemotherapy improves survival in low-risk patients, this treatment approach may be implemented in the standard of care of patients with resected CRLM since adjuvant systemic chemotherapy alone has not improved survival. The PUMP trial is registered in the Netherlands Trial Register (NTR), number: 7493 . Date of registration September 23, 2018.
- 1 August 2004
- Published by Elsevier in European Journal of Cancer
- Vol. 40 (12) , 1862-1871
Quality of life after palliative treatment for oesophageal carcinoma – a prospective comparison between stent placement and single dose brachytherapy
- 1 August 2004
- Published by Elsevier in European Journal of Cancer
- Vol. 40 (12) , 1862-1871
Quality of life after palliative treatment for oesophageal carcinoma – a prospective comparison between stent placement and single dose brachytherapy